AbbVie, Capsida Expand Collaboration in Targeted Genetic Medicines for Eye Diseases

 

• Partnership Combines AbbVie's extensive capabilities with Capsida's novel adeno-associated virus (AAV) engineering platform
• Builds upon the neurodegenerative disease partnership announced in 2021

https://www.biospace.com/article/releases/abbvie-and-capsida-biotherapeutics-expand-strategic-collaboration-to-develop-targeted-genetic-medicines-for-eye-diseases-with-high-unmet-need/